• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dual Oral Iron Chelation in Thalassemia: Need for Robust Evidence.

作者信息

Peyam Srinivasan, Bansal Deepak

机构信息

Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.

出版信息

Indian J Pediatr. 2021 Apr;88(4):319-321. doi: 10.1007/s12098-021-03698-5. Epub 2021 Mar 8.

DOI:10.1007/s12098-021-03698-5
PMID:33683580
Abstract
摘要

相似文献

1
Dual Oral Iron Chelation in Thalassemia: Need for Robust Evidence.地中海贫血的双重口服铁螯合疗法：需要有力证据
Indian J Pediatr. 2021 Apr;88(4):319-321. doi: 10.1007/s12098-021-03698-5. Epub 2021 Mar 8.
2
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.口服螯合剂地拉罗司与去铁酮联合治疗输血依赖型地中海贫血患儿铁过载的疗效和安全性：一项前瞻性观察研究。
Indian J Pediatr. 2021 Apr;88(4):330-335. doi: 10.1007/s12098-020-03442-5. Epub 2020 Jul 13.
3
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016.
4
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.使用去铁酮（L1）、去铁胺的ICOC联合治疗方案及新型螯合药物对地中海贫血铁过载进行有效新治疗。
Haematologica. 2006 Jun;91(6 Suppl):ELT04.
5
Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.每日交替使用地拉罗司和去铁酮疗法成功控制了无法治疗的输血依赖型地中海贫血患者的铁蓄积。
Am J Hematol. 2018 Oct;93(10):E338-E340. doi: 10.1002/ajh.25222. Epub 2018 Aug 14.
6
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.不同铁螯合剂对埃及铁过载β地中海贫血患儿的治疗效果。
Infect Disord Drug Targets. 2015;15(2):98-105. doi: 10.2174/1871526515666150724111721.
7
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.口服铁螯合剂及其新型组合疗法治疗儿童地中海贫血的疗效和安全性比较
Indian Pediatr. 2016 Mar;53(3):207-10. doi: 10.1007/s13312-016-0821-4.
8
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.输血依赖型地中海贫血患者不遵守铁螯合疗法的后果及成本：一项文献综述
Transfusion. 2007 Oct;47(10):1919-29. doi: 10.1111/j.1537-2995.2007.01416.x.
9
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.地拉罗司治疗非输血依赖型地中海贫血综合征患者的概况。
Drug Des Devel Ther. 2015 Dec 16;9:6475-82. doi: 10.2147/DDDT.S40694. eCollection 2015.
10
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.地拉罗司显著减少非输血依赖型地中海贫血的铁过载：一项前瞻性、随机、双盲、安慰剂对照研究的 1 年结果。
Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15.

引用本文的文献

1
Dual Oral Iron Chelation (DOIC) in Children with Transfusion-Dependent Beta Thalassemia: Real-World Efficacy Data.依赖输血的β地中海贫血患儿的双重口服铁螯合疗法（DOIC）：真实世界疗效数据
Indian J Hematol Blood Transfus. 2025 Jan;41(1):167-170. doi: 10.1007/s12288-024-01804-z. Epub 2024 Jun 20.
2
Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment.地中海贫血症与纳米诊疗学：诊断与治疗的新进展
Biosensors (Basel). 2023 Apr 1;13(4):450. doi: 10.3390/bios13040450.
3
Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.
细胞和基因治疗贫血：造血干细胞与基因编辑。
Int J Mol Sci. 2021 Jun 10;22(12):6275. doi: 10.3390/ijms22126275.